Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Sci Rep ; 13(1): 8116, 2023 05 19.
Artículo en Inglés | MEDLINE | ID: covidwho-2325002

RESUMEN

Despite advances in clinical research, the long-term effects of COVID-19 on patients are not clear. Many studies revealed persistent long-term signs and symptoms. In a survey study, 259 hospitalized confirmed COVID-19 patients between 18 and 59 years were interviewed. Demographic characteristics and complaints were studied through telephone interviews. Any patient-reported symptoms that continued or developed from 4 weeks up to 12 weeks after the onset of the disease were recorded only if they did not exist prior to infection. The 12-Item General Health Questionnaire was used for screening and assessing mental symptoms and psychosocial well-being. The mean age of participants was 43.8 ± 9.9 years. About 37% had at least one underlying disease. 92.5% showed ongoing symptoms that the most prevalent complications were hair loss (61.4%), fatigue (54.1%), shortness of breath (40.2%), altered smell (34.4%), and aggression (34.4%), respectively. In terms of factors affecting patients' complaints, there were significant differences between age, sex, and underlying disease with long-remaining complications. This study shows a high rate of long COVID-19 conditions that should be considered by physicians, policymakers, and managers.


Asunto(s)
COVID-19 , Síndrome Post Agudo de COVID-19 , Humanos , Adulto , Persona de Mediana Edad , COVID-19/epidemiología , Agresión , Sobrevivientes , Estado de Salud
2.
Emerg Infect Dis ; 27(2): 636-638, 2021 02.
Artículo en Inglés | MEDLINE | ID: covidwho-993266

RESUMEN

We determined the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an affected area in northern Iran in April 2020. Antibodies to SARS-CoV-2 were detected in 528 persons by using rapid tests. Adjusted prevalence of SARS-CoV-2 seropositivity was 22.2% (95% CI 16.4%-28.5%).


Asunto(s)
Anticuerpos Antivirales/sangre , Prueba Serológica para COVID-19/estadística & datos numéricos , COVID-19/epidemiología , SARS-CoV-2/inmunología , Anticuerpos Antivirales/inmunología , COVID-19/sangre , COVID-19/inmunología , Estudios Transversales , Composición Familiar , Femenino , Humanos , Irán/epidemiología , Masculino , Estudios Seroepidemiológicos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA